PUT - SPRINTER OPEN END - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 19:04:17 28/06/2024 BST | ||
| 5.4 EUR | -3.40% |
|
| Current month | -28.48% | ||
| 1 month | -31.65% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 5.4 | -3.40% |
| 27/06/24 | 5.59 | -1.41% |
| 26/06/24 | 5.67 | -1.22% |
| 25/06/24 | 5.74 | +6.69% |
| 24/06/24 | 5.38 | -11.95% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 07:04 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM8GFQ |
| ISIN | DE000VM8GFQ3 |
| Date issued | 12/01/2024 |
| Strike | 531 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 9.19 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.17 € |
|---|---|
| Lowest since issue | 4.22 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Certificates
- Certificat
